Purpose: To design and validate a software package to quantitate the area s
ubtended by drusen in color fundus photographs for the conduct of efficient
, accurate clinical trials in age-related macular degeneration.
Design: Algorithm and software development. Comparisons with manual methodo
logies.
Participants: Evaluation and testing on color fundus photographs from patie
nt records and from eyes enrolled in the Choroidal Neovascularization Preve
ntion Trial.
Methods: Fundus photographs of eyes with drusen were digitized, The green c
hannel was selected for maximum contrast and preprocessed with filtering an
d shade correction to minimize noise, improve contrast, and correct for ill
umination and background inhomogeneities. Local thresholding and region-gro
wing algorithms identified drusen, Multiple levels of supervision were inco
rporated to maximize robustness, accuracy, and validity. Validation studies
compared computer-assisted with manual grading by an experienced grader. I
ntraclass correlation coefficients were calculated as a measure of the conc
ordance between manual and computer-assisted fundus gradings,
Main Outcome Measures: Drusen area and concordance with manual grading.
Results: Automated supervised image analysis offers extreme robustness and
accuracy, Most images were segmented with little or no supervision, with pr
ocessing times on the order of 5 seconds. More complicated images required
supervision and a total analysis time varying from 20 seconds to 5 minutes,
with most of this time devoted to inspection and comparison. Interactive i
mage processing affords arbitrarily close concordance with manual drusen id
entification, with calculated intraclass correlation coefficients of 0.92 a
nd 0.93 for comparison of manual with automated, supervised grading by two
observers.
Conclusions: Automated supervised fundus image analysis is an efficient, ro
bust, valid technique for drusen quantitation from color fundus photographs
. This approach should prove useful in the conduct of efficient accurate cl
inical trials for age-related macular degeneration.